Lantern Pharma (LTRN) Other Non-Current Assets (2019 - 2026)

Lantern Pharma (LTRN) has reported Other Non-Current Assets for 8 consecutive years, with $54827.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Assets rose 49.24% year-over-year to $54827.0; the trailing twelve-month figure through Jun 2026 stood at $54827.0 (up 49.24% YoY), and the FY2025 full-year result was $88431.0, up 140.71% from the prior year.
• Other Non-Current Assets steadied at $54827.0 in Q2 2026 per LTRN's latest filing, from $54827.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $541180.0 in Q1 2022 and bottomed at $25869.0 in Q3 2023.
• Historically, Other Non-Current Assets has averaged $207693.2 across 5 years, with a median of $45782.5 in 2024.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets soared 2925.21% in 2022, then sank 95.22% in 2023.
• Over 5 years, Other Non-Current Assets stood at $541180.0 in 2022, then tumbled by 95.22% to $25869.0 in 2023, then soared by 42.02% to $36738.0 in 2024, then surged by 140.71% to $88431.0 in 2025, then plunged by 38.0% to $54827.0 in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $54827.0, $54827.0, and $88431.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.